RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Acceleron Pharma P/E 2024

Acceleron Pharma P/E

-63.55

Acceleron Pharma Dividend yield

Ticker

XLRN

ISIN

US00434H1086

WKN

A1W5LE

As of Jun 2, 2024, Acceleron Pharma's P/E ratio was -63.55, a 0% change from the 0 P/E ratio recorded in the previous year.

The Acceleron Pharma P/E history

Acceleron Pharma Aktienanalyse

What does Acceleron Pharma do?

Acceleron Pharma Inc. is a biopharmaceutical company based in Cambridge, Massachusetts. It was founded in 2003 by a group of scientists specializing in drug development in the fields of oncology and hematology. The company's business model is based on the discovery and development of innovative therapeutic solutions, particularly in the areas of oncology and rare diseases. They use a wide range of technologies to identify potential target molecules and test their effectiveness. Acceleron Pharma operates in three different business areas: oncology, hemoglobinopathies, and musculoskeletal diseases. In oncology, the company focuses on developing drugs to treat cancers such as multiple myeloma or pancreatic cancer. The hemoglobinopathies division of Acceleron Pharma develops therapies for patients with rare blood disorders such as beta-thalassemia and sickle cell disease. In the field of musculoskeletal diseases, the company is working on developing therapies for muscle, connective tissue, and joint disorders. One of Acceleron Pharma's key products is the drug Reblozyl, which was developed in collaboration with Bristol Myers Squibb. Reblozyl is the first FDA-approved medication for the treatment of anemia in patients with beta-thalassemia. The company has also entered into a partnership agreement with Celgene to develop medications for the treatment of inflammatory bowel diseases. Acceleron Pharma has also successfully partnered with other major pharmaceutical companies such as Pfizer and Sanofi in the past. Through these partnerships, the company has provided its technology platform for the discovery and development of drugs for various indications such as cancer and muscle diseases. Acceleron Pharma is a fast-growing company dedicated to researching and developing innovative therapies for rare diseases. With a wide range of technologies and a strong pipeline of clinical candidates, the company is well-equipped to treat patients affected by these rare diseases. Acceleron Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Acceleron Pharma's P/E Ratio

The Price to Earnings (P/E) Ratio of Acceleron Pharma is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Acceleron Pharma's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Acceleron Pharma is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Acceleron Pharma’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Acceleron Pharma Stock

What is the price-to-earnings ratio of Acceleron Pharma?

The price-earnings ratio of Acceleron Pharma is currently -63.55.

How has the price-earnings ratio of Acceleron Pharma changed compared to last year?

The price-to-earnings ratio of Acceleron Pharma has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Acceleron Pharma high compared to other companies?

Yes, the price-to-earnings ratio of Acceleron Pharma is high compared to other companies.

How does an increase in the price-earnings ratio of Acceleron Pharma affect the company?

An increase in the price-earnings ratio of Acceleron Pharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Acceleron Pharma affect the company?

A decrease in the price-earnings ratio of Acceleron Pharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Acceleron Pharma?

Some factors that influence the price-earnings ratio of Acceleron Pharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Acceleron Pharma pay?

Over the past 12 months, Acceleron Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Acceleron Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Acceleron Pharma?

The current dividend yield of Acceleron Pharma is .

When does Acceleron Pharma pay dividends?

Acceleron Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Acceleron Pharma?

Acceleron Pharma paid dividends every year for the past 0 years.

What is the dividend of Acceleron Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Acceleron Pharma located?

Acceleron Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Acceleron Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Acceleron Pharma from 6/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/2/2024.

When did Acceleron Pharma pay the last dividend?

The last dividend was paid out on 6/2/2024.

What was the dividend of Acceleron Pharma in the year 2023?

In the year 2023, Acceleron Pharma distributed 0 USD as dividends.

In which currency does Acceleron Pharma pay out the dividend?

The dividends of Acceleron Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Acceleron Pharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Acceleron Pharma

Our stock analysis for Acceleron Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acceleron Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.